Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Oct 17:2018:bcr2018226588.
doi: 10.1136/bcr-2018-226588.

Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis

Jarrett Madeley  1 , Georgina Hodges  2 , Andrew Birchley  2
Affiliations
Case Reports

Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis

Jarrett Madeley et al. BMJ Case Rep. .

Abstract

This case illustrates a 36-year-old man who presented with a factor VIII (FVIII) inhibitor (acquired haemophilia A) with cutaneous bleeding and a significant thigh haematoma. No traditional risk factors for the development of a FVIII inhibitor were identified. However, previous treatment with alemtuzumab for multiple sclerosis was noted in the patient's history. Alemtuzumab is an anti-CD52 monoclonal antibody and is known to be associated with the development of a number of autoimmune conditions, with a delay in onset of these conditions as long as 5 years after the cessation of treatment. To our knowledge, there have only been three previously documented cases of a FVIII inhibitor in the setting of alemtuzumab therapy. This case adds further evidence to the current body of literature suggesting alemtuzumab as a causative agent for the development of an FVIII inhibitor.

Keywords: drugs: cns (not psychiatric); haematology (incl blood transfusion); multiple sclerosis; neurology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017;10:343–59. 10.1177/1756285617722706 - DOI - PMC - PubMed
    1. Thota S, Patel BJ, Sadaps M, et al. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. Br J Haematol 2017. 10.1111/bjh.14907 - DOI - PMC - PubMed
    1. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 2017;92:946–65. 10.1002/ajh.24826 - DOI - PubMed
    1. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007;109:2643–2548. 10.1182/blood-2006-07-035766 - DOI - PubMed
    1. Madurka I, Elek J, Schönauer N, et al. Urgent lung transplantation in severe acute respiratory failure based on rapidly progressive interstitial lung disease: a case report. Transplant Proc 2017;49:1544–8. 10.1016/j.transproceed.2017.06.020 - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts